Latest News

December 2011: Cellzome awarded UK's Technology Strategy Board grant as part of the Regenerative Medicine Programme more

December 2011: Cellzome Founder wins EU Women Innovators Award. Dr. Gitte Neubauer awarded first prize for the foundation of Cellzome more

Meet Cellzome at

European Commission Innovation Convention 2011, Brussels, Belgium more

Cellzomers

Find out more about Cellzome and job openings

Downloads (pdf)

Corporate factsheet
Episphere™ factsheet
Kinobeads™ factsheet

Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology.

Drug Discovery and Technology

Cellzome's technologies work with native proteins in a true physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases and include:

Kinobeads technology works in physiological settings to direct the design of potent and selective small molecule drug candidates.

Episphere comprises a suite of quantitative proteomics technologies for the discovery of drug candidates for epigenetic targets

Partnering and Collaborations

Cellzome maintains the highest levels of scientific expertise and has several active collaborations with leading academic laboratories globally.

The Company has a track record in delivering significant collaborations with top pharma­ceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. If you are interested in discussing collaborative or partnering opportunities contact business@cellzome.com